Novavax, Inc. (NASDAQ:NVAX)

CAPS Rating: 1 out of 5

A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.

Recs

0
Player Avatar Lawrence56 (< 20) Submitted: 3/18/2011 1:46:03 PM : Outperform Start Price: $2.56 NVAX Score: -53.37

2yr gov contract with possible extension of 2 additional

Featured Broker Partners


Advertisement